SPRY

ARSC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$16.00

+128.6% vs current

Most likely

Base case

45%

Probability

Target price

$10.50

+50.0% vs current

B-

Bear case

30%

Probability

Target price

$5.50

-21.4% vs current

AI sentiment snapshot

Latest data as of 2026-06-30

AI commentary

Sentiment weakened materially after the June 24, 2026 company update: the primary source confirmed no new July-cycle commercial coverage wins, and trusted press coverage tied a roughly 24% June 25 share drop to that disappointment. The tone is no longer a simple positive-access setup; it is now a cautious monitoring story where near-term price action likely depends on whether demand keeps growing without the expected CVS-style access inflection. No reliable social dataset was provided, so confidence should lean on company disclosures and limited trusted coverage rather than message-board tone.

RankAlpha Sentiment Codex - 2026-06-30

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-01catalystBack-to-school demand must hold up despite no July 1 commercial formulary winHigh impact

ARS said no new commercial formulary additions or coverage decisions were issued for neffy in the July 1, 2026 cycle, but also said demand continued to grow, Florida Medicaid adds unrestricted coverage effective July 1, and the $199 retail cash option remains in place; the next few months now become a cleaner test of whether base-business demand can offset payer disappointment. [#IR-2026-06-24]

2026-11-15catalystQ4 2026 CSU interim data is the main non-neffy pipeline proof pointHigh impact

ARS said the Phase 2b CSU interim population is fully enrolled and remains on track for a Q4 2026 readout, making it the clearest diversification milestone beyond the neffy launch story. [#SEC-8K-2026-05-15]

2026-12-31eventFurther payer access progress remains the key rerating variableHigh impact

Management previously said the CVS Caremark proposal was in the final stages of approval and framed access expansion as central to adoption, but the June 24 update disclosed no new July-cycle commercial wins and a need to continue payer discussions; any later inclusion would matter disproportionately for sentiment because prior authorization remains a core friction point. [#SEC-8K-2026-05-15] [#IR-2026-06-24]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-30 • Updated nightlySource: Internal modelMethodology